Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy.
Bruce W. Dana(University of Oklahoma Health Sciences Center), R I Fisher, Thomas P. Miller, Elizabeth C. Chase, Bharat N. Nathwani(City Of Hope National Medical Center), Steve Dahlberg(Georgetown University), Charles A. Coltman(Wilford Hall Ambulatory Surgical Center)
Cited by 193
Related Papers
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells
|New England Journal of Medicine|2004|1.4k
Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma
|The Journal of Experimental Medicine|2003|1.1k